Methods for modeling in vitro percutaneous absorption of drugs from local dosage forms

Abstract

Transdermal absorption of medicinal substances (LP) proceeds as a two-stage process, consisting of penetration of drugs from dosage forms (LF) into the skin and absorption itself [4]. In biopharmaceutical studies, when choosing the optimal composition of dermal DF and studying the role of pharmaceutical factors affecting the release of drugs from LF, dialysis methods (equilibrium and flow) are widely used, designed to simulate both stages of transdermal absorption. A number of requirements are imposed on model membranes, which are a diffusion barrier: they must have an insignificant thickness and a small internal volume so that the amount of LS remaining in it is minimal; be sufficiently resistant to mechanical stress so that during the experiment its integrity is not violated; should provide a correlation between the results of experiments in vivo and in vitro [5, 6, 10].

Keywords

Kazan Medical archive

References

[1] Агаев Ф.Б., Абдулова Э.Б.//Азерб. мед. ж. — 1981. — №4,- С. 59-61.

[2] Борищук В. О., Головк'т В. О.//Фармац. ж. — 1990. — № 6. — С. 65—66 (укр.).

[3] Егорова С. II., Зигапщииа Л.Е., Кадырова /^.//Фармация. — 1998. — № 5. — С. 18—20.

[4] Aiache J.M.//Ann. Cardiol. Angeiol. Paris. — 1997. — Vol. 46.-P. 441-449.

[5] Bronaugh R.L., Stewart R.F.//1. Pharm. Sci. — 1985. — Vol.4.-P. 1062-1066.

[6] Bronaugh R.L., Stewart R.F., Congdon E.R.//ToZ\co\. and Appl. Pharmacol. — 1982. — Vol. 62. — P. 481.

[7] Ceschel G.C., Maffei P., Moretti M.D.L. et al.// Farm. Vesth. — Vol. 48. — Special issue. Proceed 2-nd Central European Symposium on Pharmaceutical Technology. — P. 240—241.

[8] Franz T.J., Lehman P.A., Franz S.F. et al.// Arch. Dermatol. — 1996. — Vol. 132. — P. 901—905.

[9] Heard C.M., Brain K, Nicholls P. J. etal.//l. Pharm. and Pharmacol. — 1997. — Vol. 49. — P. 27.

[10] Hippius M.,Uhlemann C, Smolensk! U. et al.// Int.J. Clin. Pharmacol. Ther. — 1998. — Vol. 36. — P. 107—111.

[11] Ito Y., Ogiso T, Iwaki M. et al.// Biol. Pharm. Bull. — 1993.-Vol. 16.-P. 583-588.

[12] Juhasz J., Mahashabde S., Sequeira /.//Drug Dev. and Ind. Pharm. - 1996. - Vol. 22. - P. 1139-1144.

[13] Kecsker A., Blitstein-Willinger E.// Arzneimittel- forschung. — 1993. — Vol. 43. — P. 450—454.

[14] Lien E.J., Gao //.//Pharm. Res. — 1995. — Vol. 12. — P. 583-587.

[15] Lin H.H., Hsu L.R., Wu P. C. etal.//Bio\. Pharm. Bull. - 1995.-Vol. 18.-P. 1560-1565.

[16] Mura P., Nassini C, Proietti D. et al.// Pharm. Acta Helv. — 1996. — Vol. 71. — P. 147—154.

[17] Pulat M., Abbasoglu U.//1. Biomater. Appl. — 1995. — Vol. 9.-P. 363-371.

[18] Ramis J., Conte L., Sedago X. et al.// Arzneimittel- forschung. — 1997. — Vol. 47. — P. 1139—1144.

[19] Realdon N., RagazziE., Dal-Zotto M. e/n/.//Phannazie. — 1995.-Vol. 50.-P. 603-606.

[20] Realdon N., Ragazz.! E., Dal-Zotto M. eM/.//Pharmazie. — 1996.-Vol. 51.-P. 113-116.

[21] Roy S.D., Roos E., Sharma K.//I. Pharm. Sci. — 1994. — Vol. 83.-P. 126-130.

[22] Sarpotdar P.P., Gaskill J. L., Giannini R.P.//F Pharm. Sci. - 1986. - Vol. 75. - P. 26-28.

[23] Sieh Hearan, Jun H. W.//1. Pharm. Sci. — 1996. — Vol. 48.-P. 812-816.

[24] Tauber U., Weiss C., Matthes //.//Skin Pharmacol. — 1993.-Vol. 6.-P. 276-281.

[25] Volpato N.M., Santi P., Colombo P.// Pharm. Res. — 1995. - Vol. 12. - P. 1623-1627.

[26] Yamaguchi Y., Usami T, Natsume H. et al.// Chern. Pharm. Bull. Tokyo. - 1997. - Vol. 45. - P. 537-541.

[27] ZatzJ.L., Varsano J., Shah FP.//Phaim. Dev. Technol. — 1996.-Vol. l.-P. 293-298.

RIGHTS & PERMISSIONS

Eco-Vector